自體和非幹細胞治療市場：按應用和地區分類

預計到 2026 年，自體和非幹細胞療法的市場規模將達到 69 億美元，到 2033 年將達到 142 億美元。預計 2026 年至 2033 年的複合年成長率將達到 14.8%。

自體幹細胞和非幹細胞療法市場利用患者自身的細胞來促進組織修復、調節免疫反應和控制疾病。透過將採集的細胞輸回患者體內，自體療法最大限度地降低了免疫排斥的風險。研究人員對自體幹細胞進行了廣泛的研究，一項對印度相關研究的系統性綜述表明，在所評估的幹細胞治療方法中，自體細胞療法佔據了相當大的比例。

非幹細胞療法利用軟骨細胞、纖維母細胞、角質形成細胞、肝細胞和免疫細胞等特化細胞來滿足多種治療需求。這些方法支持再生醫學、癌症治療、創傷治療和組織修復。研發人員越來越重視標準化生產、病人安全和合適的病人選擇。監管機構在批准再生醫學產品用於更廣泛的治療用途之前，也要求提供可靠的臨床證據。

市場動態

個人化醫療的日益普及正在推動市場需求。醫療機構擴大採用自體療法，即使用患者自身的細胞，因為這降低了對捐贈者相容性的要求，並減輕了免疫排斥的風險。研發人員正在推動造血幹細胞移植、CAR-T療法、腫瘤浸潤淋巴細胞療法和再生醫學等領域的應用。美國食品藥物管理局（FDA）已批准自體和異體細胞療法作為再生醫學的一部分，並透過加速再生醫學核准（RMAT）流程支持針對嚴重的有前景的療法。這些監管支持正在促使研發人員投資於患者特異性細胞療法。

技術進步正在拓展治療應用領域。研發人員致力於改善細胞分離、處理、增殖、表徵和自動化生產，以提高治療的一致性和擴充性。自體CAR-T療法清楚地展現了這一進展，例如NexCAR19等產品將患者來源的細胞療法從研究階段推進到臨床實踐階段。研發人員也正在推動非幹細胞療法，例如免疫療法和組織修復應用，進一步拓展治療機會。這些創新正推動市場朝向標靶性強、標準化且具商業性可行性的治療模式發展。

複雜的生產和監管要求阻礙了自體療法的推廣應用。與傳統藥物相比，自體療法在物流和成本方面都面臨挑戰，因為醫療機構必須為每位患者採集、處理、檢測和重新注射細胞。美國食品藥物管理局 (FDA) 要求研發者證明細胞療法的生產品質、安全性、有效性和臨床療效。該機構還報告了與未經批准的再生醫學產品相關的嚴重不利事件，例如感染疾病、失明和腫瘤形成。因此，研發者必須加強生產可靠性和監管合規性，才能實現永續的臨床應用。

本次調查的主要特點

• 該研究重點分析了各個細分市場的潛在商機，並為參與自體幹細胞和非幹細胞治療市場的相關人員提供了一個有吸引力的投資提案矩陣。
• 本研究深入分析了市場促進因素、限制因素、機會、新興技術、臨床進展、細胞處理創新、再生醫學應用、監管趨勢、區域展望以及主要市場參與企業採取的競爭策略。
• 本研究根據公司概況、治療組合、近期趨勢、臨床進展、產品平臺、策略性舉措和技術發展，分析了自體幹細胞和非幹細胞療法市場的主要參與者。
• 透過利用本報告中提出的見解，醫療保健提供者、生技公司、製藥公司、投資者、研究人員和經營團隊可以就療法開發、臨床投資、生產擴張、技術採用、策略合作夥伴關係和市場進入做出明智的決策。
• 《自體幹細胞和非幹細胞療法市場》報告的目標相關人員廣泛，包括投資者、製藥公司、生物技術公司、細胞療法開發公司、醫療保健提供者、研究機構、契約製造組織 (CMO)、監管機構、新市場參與企業和金融分析師。
• 相關人員可以透過「自體幹細胞和非幹細胞療法市場」報告中提出的分析框架、競爭基準、臨床管線評估、技術評估、監管分析和市場估值矩陣做出明智的策略決策。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 促進因素
  • 抑制因子
  • 市場機遇
• 影響分析
• 市場趨勢
• 主要進展
• 產品核准
• 合作關係、併購
• 監理情勢
• PEST分析
• 波特五力分析
• 流行病學
• 穩健的管道分析

第4章 全球自體與非幹細胞療法市場：依應用領域分類，2021-2033年

• 神經退化性疾病
• 心血管疾病
• 癌症與自體免疫疾病
• 皮膚移植
• 感染疾病

第5章 全球自體與非幹細胞療法市場：按地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲國家
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太國家
• 中東
  • GCC
  • 以色列
  • 其他中東國家
• 非洲
  • 北非
  • 中非
  • 南非

第6章 競爭情勢

• 熱圖分析
• 市佔率分析
• 公司簡介
  • Caladrius Biosciences
  • Vericel Corporation
  • Fibrocell Science, Inc.
  • Genzyme Corporation
  • BrainStorm Cell Therapeutics
  • Regeneus Ltd.
  • Dendreon Corporation
• 分析師意見

第7章

• 參考
• 調查方法
• 關於本公司

Autologous Stem Cell And Non-Stem Cell Based Therapies Market is estimated to be valued at USD 6.9 Bn in 2026 and is expected to reach USD 14.2 Bn by 2033, growing at a compound annual growth rate (CAGR) of 14.8% from 2026 to 2033.

The autologous stem cell and non-stem cell based therapies market uses a patient's own cells to promote tissue repair, regulate immune responses, and manage diseases. By returning harvested cells to the same patient, autologous therapies can help minimize immune-rejection concerns. Researchers have extensively studied autologous stem cells, with a systematic review of Indian studies reporting that autologous cells represented a substantial share of evaluated stem cell therapy approaches.

Non-stem cell therapies use specialized cells, including chondrocytes, fibroblasts, keratinocytes, hepatocytes, and immune cells, to address various therapeutic needs. These approaches support regenerative medicine, cancer treatment, wound healing, and tissue repair. Developers increasingly prioritize standardized manufacturing, patient safety, and appropriate patient selection. Regulatory authorities also demand strong clinical evidence before approving regenerative medicine products for wider therapeutic use.

Market Dynamics

Rising adoption of personalized medicine drives demand: Healthcare providers increasingly use autologous therapies because these treatments rely on patients' own cells, reducing donor-matching requirements and potential immune-rejection concerns. Developers are advancing applications across hematopoietic stem-cell transplantation, CAR-T therapies, tumor-infiltrating lymphocytes, and regenerative medicine. The FDA recognizes autologous and allogeneic cell therapies under regenerative medicine and uses the RMAT pathway to support promising treatments for serious conditions. This regulatory support encourages developers to invest in patient-specific cellular therapies.

Technological advances expand therapeutic applications: Developers are improving cell isolation, processing, expansion, characterization, and automated manufacturing to enhance treatment consistency and scalability. Autologous CAR-T therapies demonstrate this progress, with products such as NexCAR19 translating patient-derived cellular treatments from research into clinical practice. Developers are also advancing non-stem cell approaches, including immune-cell therapies and tissue-repair applications, which broaden therapeutic opportunities. These innovations are moving the market toward targeted, standardized, and commercially viable treatment models.

Complex manufacturing and regulatory requirements restrain adoption: Autologous therapies require providers to collect, process, test, and reinfuse cells for each patient, creating logistical and cost challenges compared with conventional medicines. The FDA requires developers to demonstrate manufacturing quality, safety, potency, and clinical efficacy for cellular therapies. The agency has also reported serious adverse outcomes linked to unapproved regenerative products, including infections, blindness, and tumor formation. Consequently, developers must strengthen manufacturing reliability and regulatory compliance to achieve sustainable clinical adoption.

Key Features of the Study

• It highlights potential revenue opportunities across various market segments and provides attractive investment proposition matrices for stakeholders involved in the Autologous Stem Cell and Non-Stem Cell Based Therapies Market.
• This study offers key insights into market drivers, restraints, opportunities, emerging technologies, clinical advancements, cell-processing innovations, regenerative medicine applications, regulatory developments, regional outlook, and competitive strategies adopted by leading market participants.
• It profiles key players in the Autologous Stem Cell and Non-Stem Cell Based Therapies Market based on company overview, therapy portfolio, recent developments, clinical advancements, product pipeline, strategic initiatives, and technological developments.
• Key companies covered as part of this study include Caladrius Biosciences, Vericel Corporation, Fibrocell Science, Inc., Genzyme Corporation, BrainStorm Cell Therapeutics, Regeneus Ltd., and Dendreon Corporation.
• Insights from this report enable healthcare providers, biotechnology companies, pharmaceutical companies, investors, researchers, and management teams to make informed decisions regarding therapy development, clinical investments, manufacturing expansion, technology adoption, strategic partnerships, and market entry.
• The Autologous Stem Cell and Non-Stem Cell Based Therapies Market report serves a wide range of stakeholders, including investors, pharmaceutical companies, biotechnology firms, cell therapy developers, healthcare providers, research institutions, contract manufacturing organizations, regulatory bodies, new market entrants, and financial analysts.
• Stakeholders can make well-informed strategic decisions through the analytical frameworks, competitive benchmarking, clinical pipeline assessment, technology evaluation, regulatory analysis, and market evaluation matrices presented in the Autologous Stem Cell and Non-Stem Cell Based Therapies Market report.

Market Segmentation

• By application (Revenue, USD Bn, 2021-2033)
• Neurodegenerative diseases
• Cardiovascular diseases
• Cancer and autoimmune diseases
• Skin transplantation
• Infectious disease
• By Region (Revenue, USD Bn, 2021-2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • Central Africa
  • North Africa
• Key Players
• Caladrius Biosciences
• Vericel Corporation
• Fibrocell Science, Inc.
• Genzyme Corporation
• BrainStorm Cell Therapeutics
• Regeneus Ltd.
• Dendreon Corporation.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Application
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Product Approval
• Collaboration/Merge/Acquisition
• Regulatory Landscape
• PEST Analysis
• Porter's Five Forces Analysis
• Epidemiology
• Robust Pipeline Analysis

4. Global Autologous Stem Cell And Non-Stem Cell Based Therapies Market, By Application, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022- 2033
  • Segment Trends
• Neurodegenerative diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Cardiovascular diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Cancer and autoimmune diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Skin transplantation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Infectious disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

5. Global Autologous Stem Cell And Non-Stem Cell Based Therapies Market, By Region, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2022-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
    • North Africa
    • Central Africa
    • South Africa

6. Competitive Landscape

• Heat Map Analysis
• Market Share Analysis
• Company Profile
  • Caladrius Biosciences
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Vericel Corporation
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Fibrocell Science, Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Genzyme Corporation
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • BrainStorm Cell Therapeutics
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Regeneus Ltd.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Dendreon Corporation
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
• Analyst Views

7. Section

• References
• Research Methodology
• About Us